PPD inks deal to buy Russian CRO

PPD says it's inked a deal to buy InnoPharm, an independent contract research organization based in Russia. The buyout gives PPD reach into the Russian and Ukrainian markets. "With more than 143 million people in Russia alone, Eastern Europe is a high-growth market for clinical trials and a region PPD has targeted for expansion," said Fred Eshelman, chief executive officer of PPD. InnoPharm employs about 300 people.

- check out the release
- here's the AP report

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.